Comparison of iatrogenic pain between rotavirus vaccination before and after vaccine injection in 2-month-old infants

Yin, Hui Chu; Shih, Whei Mei; Lee, Hsiu Lan; Yang, Huei Jing; Chen, Yu Li; Cheng, Shao Wen; Yang, Chun Yuh; Chiu, Ya Wen; Weng, Yi Ming

doi:10.1080/21645515.2016.1267082

Cited by 7 publications

(1 citation statement)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies have shown that giving something sweet like sucrose solution decrease the pain response to the injectable vaccine administration. 17,18 A study proposed that sucrose reduces pain only during the young infant period but not after 4 month of age. 19 This is because endogenous opioids are released that are activated by sweet taste and blunts pain response.…”

Section: Discussionmentioning

confidence: 99%

Evaluating the Pain Responses among Infants Receiving Rotavirus Vaccine Versus Oral Polio Vaccine Before the Administration of Pentavalent Vaccine with Inactivated Polio Vaccine: A Randomized Study

2020

IJPHRD

View full text Add to dashboard Cite

Background: Vaccination is the most common painful interventions in infants.Non-pharmacological interventions to alleviate pain rely on the inhibition of pain signaling.Objective: To compare the acute pain response of the infants receiving oral rotavirus vaccine versus oral polio vaccine before administration of injectable vaccines. Method:This was a randomized control study conducted for a period of six months at the immunization center of a tertiary care teaching hospital. Children who are receiving rotavirus vaccine, inactivated polio vaccine (IPV), Pentavac® [Diphtheria+ Tetanus+wholecellpertussis(DTwP) + Hepatitis B (Hep B)+ Hemophilus Influenza B (HiB)] and oral polio vaccine (OPV) belong to the age group of 6 to 14 weeks visiting the study site for routine immunization were included in the study. The enrolled subjects were randomized into group A and group B using blocked randomization method. The responses of the infants were video graphed for 10seconds before and 30seconds after giving the vaccination. The recorded videos were coded and given to a research panel for scoring the pain response of infants on the basis of modified behavior pain scale (MBPS). The pain response scores were compared between the groups.Results: Mean post vaccination MBPS in group A was 7.72 1.01 and in group B was 7.88 0.90. There was no statistically significant difference in pain response was found between group A and Group B children (P 0.55). Conclusion:Sequence of administration of oral polio vaccine and rotavirus vaccine did not impact the pain response following the administration of Pentavac® and inactivated polio vaccine among infants.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluating the Pain Responses among Infants Receiving Rotavirus Vaccine Versus Oral Polio Vaccine Before the Administration of Pentavalent Vaccine with Inactivated Polio Vaccine: A Randomized Study

2020

IJPHRD

View full text Add to dashboard Cite

show abstract

Non-pharmacological management of infant and young child procedural pain

Riddell

Bucsea

Shiff

et al. 2023

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Vaccines for preventing rotavirus diarrhoea: vaccines in use

Soares‐Weiser

Bergman

Henschke

et al. 2019

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

BackgroundRotavirus results in more diarrhoea‐related deaths in children under five years than any other single agent in countries with high childhood mortality. It is also a common cause of diarrhoea‐related hospital admissions in countries with low childhood mortality. Rotavirus vaccines that have been prequalified by the World Health Organization (WHO) include a monovalent vaccine (RV1; Rotarix, GlaxoSmithKline), a pentavalent vaccine (RV5; RotaTeq, Merck), and, more recently, another monovalent vaccine (Rotavac, Bharat Biotech).ObjectivesTo evaluate rotavirus vaccines prequalified by the WHO (RV1, RV5, and Rotavac) for their efficacy and safety in children.Search methodsOn 4 April 2018 we searched MEDLINE (via PubMed), the Cochrane Infectious Diseases Group Specialized Register, CENTRAL (published in the Cochrane Library), Embase, LILACS, and BIOSIS. We also searched the WHO ICTRP, ClinicalTrials.gov, clinical trial reports from manufacturers' websites, and reference lists of included studies and relevant systematic reviews.Selection criteriaWe selected randomized controlled trials (RCTs) in children comparing rotavirus vaccines prequalified for use by the WHO versus placebo or no intervention.Data collection and analysisTwo review authors independently assessed trial eligibility and assessed risks of bias. One review author extracted data and a second author cross‐checked them. We combined dichotomous data using the risk ratio (RR) and 95% confidence interval (CI). We stratified the analysis by country mortality rate and used GRADE to evaluate evidence certainty.Main resultsFifty‐five trials met the inclusion criteria and enrolled a total of 216,480 participants. Thirty‐six trials (119,114 participants) assessed RV1, 15 trials (88,934 participants) RV5, and four trials (8432 participants) Rotavac.RV1Children vaccinated and followed up the first year of lifeIn low‐mortality countries, RV1 prevents 84% of severe rotavirus diarrhoea cases (RR 0.16, 95% CI 0.09 to 0.26; 43,779 participants, 7 trials; high‐certainty evidence), and probably prevents 41% of cases of severe all‐cause diarrhoea (RR 0.59, 95% CI 0.47 to 0.74; 28,051 participants, 3 trials; moderate‐certainty evidence). In high‐mortality countries, RV1 prevents 63% of severe rotavirus diarrhoea cases (RR 0.37, 95% CI 0.23 to 0.60; 6114 participants, 3 trials; high‐certainty evidence), and 27% of severe all‐cause diarrhoea cases (RR 0.73, 95% CI 0.56 to 0.95; 5639 participants, 2 trials; high‐certainty evidence).Children vaccinated and followed up for two yearsIn low‐mortality countries, RV1 prevents 82% of severe rotavirus diarrhoea cases (RR 0.18, 95% CI 0.14 to 0.23; 36,002 participants, 9 trials; high‐certainty evidence), and probably prevents 37% of severe all‐cause diarrhoea episodes (rate ratio 0.63, 95% CI 0.56 to 0.71; 39,091 participants, 2 trials; moderate‐certainty evidence). In high‐mortality countries RV1 probably prevents 35% of severe rotavirus diarrhoea cases (RR 0.65, 95% CI 0.51 to 0.83; 13,768 participants, 2 trials; high‐certainty ev...

show abstract

Comparison of iatrogenic pain between rotavirus vaccination before and after vaccine injection in 2-month-old infants

Cited by 7 publications

References 29 publications

Evaluating the Pain Responses among Infants Receiving Rotavirus Vaccine Versus Oral Polio Vaccine Before the Administration of Pentavalent Vaccine with Inactivated Polio Vaccine: A Randomized Study

Evaluating the Pain Responses among Infants Receiving Rotavirus Vaccine Versus Oral Polio Vaccine Before the Administration of Pentavalent Vaccine with Inactivated Polio Vaccine: A Randomized Study

Non-pharmacological management of infant and young child procedural pain

Vaccines for preventing rotavirus diarrhoea: vaccines in use

Contact Info

Product

Resources

About